- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Don't Forget the Feet
National Report - A new study has found a significant discrepancy in survival rates between two groups of patients with melanoma. The five-year survival rate of patients with malignant melanoma on the leg, knee, or thigh was 84 percent, while the survival rate for patients with melanoma of the foot or ankle was 52 percent, said Susan M. Walsh, D.P.M., one of the authors of the study.
Related Videos
Recapping the Evolving Treatment Landscape for Atopic Dermatitis
Sunscreen Ingredients for UV and Visible Light Protection
The Solar Spectrum and Impact on Skin Health
Discussing Efficacy and Safety of JAK Inhibitors With Patients and Caregivers
Patient Considerations for Selecting Treatment for a 16-Year-Old Male With Severe Alopecia Areata
Future Directions for Pediatric Atopic Dermatitis Management and Research
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
The JAK-STAT Signaling Pathway and Its Role in Atopic Dermatitis
Selecting Systemic Therapy for Patients with Moderate to Severe Atopic Dermatitis
Pipeline Updates on the Horizon From Arcutis Biotherapeutics
Related Content
